首页> 外文期刊>Venture Capital: an international journal of entrepreneurial finance >Technology spillovers and capital gains in corporate venture capital investments: evidence from the biopharmaceutical industry
【24h】

Technology spillovers and capital gains in corporate venture capital investments: evidence from the biopharmaceutical industry

机译:技术溢出率和企业风险投资投资的资本收益:来自生物制药业的证据

获取原文
获取原文并翻译 | 示例
           

摘要

Using a framework combining the real option perspective and appropriation concerns raised in the entrepreneurial finance literature, we find that technology spillovers and capital gains created by corporate venture capital (CVC) investments are positively related with each other in the biopharmaceutical industry. However, this positive relationship is significantly decreased or becomes negative when CVC investments are made with solely financial objectives or in early-stage startups. This study provides evidence that the nature of the relationship between technology spillovers and capital gains that constitute the corporate investors' total returns created by CVC investments.
机译:使用框架结合了创业金融文学中提出的真实选择的视角和拨款问题,我们发现,企业风险投资(CVC)投资所创造的技术溢出和资本收益在生物制药业中彼此正相关。 然而,当CVC投资或在早期初创企业中,这种积极关系显着下降或变得负面。 本研究提供了证据表明,构成企业投资者的技术溢出效果与资本增益之间的性质,由CVC投资产生的企业投资者的总回报。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号